6533b7dcfe1ef96bd1271e9d

RESEARCH PRODUCT

Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib

Caterina MusolinoElena TirròElena TirròAgostino AntolinoBruno MartinoMichele MassiminoMichele MassiminoValentina ZammitSergio SiracusaAntonio SpitaleriStefana ImperaMaria Stella PennisiVincenzo AccursoMaurizio MussoGiuseppe MineoFerdinando PorrettoStefania StellaStefano ForteFrancesco Di RaimondoSilvia Rita VitaleSabina RussoFabio StagnoLivia ManzellaPaolo VigneriAlessandra MalatoDonato Mannina

subject

Male0301 basic medicineOncologyTreatment outcomeFusion Proteins bcr-ablAntineoplastic Agentlcsh:ChemistryBcr abl10302 clinical medicinehemic and lymphatic diseasesimatinib mesylateBCR-ABL1; European Leukemia Net; chronic myeloid leukemia; early molecular response; imatinib mesylatelcsh:QH301-705.5<i>BCR-ABL1</i>SpectroscopyAged 80 and overGeneral MedicineMiddle AgedComputer Science ApplicationsTreatment Outcome030220 oncology & carcinogenesisFemaleHumanmedicine.drugAdultmedicine.medical_specialtyProtein Kinase InhibitorAntineoplastic AgentsArticleCatalysisEuropean Leukemia NetInorganic Chemistry03 medical and health scienceschronic myeloid leukemiaLeukemia Myelogenous Chronic BCR-ABL PositiveInternal medicineBiomarkers TumormedicineHumansIn patientRNA MessengerPhysical and Theoretical ChemistryProtein Kinase InhibitorsMolecular BiologyAgedbusiness.industryOrganic ChemistryImatinibBCR-ABL1030104 developmental biologyImatinib mesylatelcsh:Biology (General)lcsh:QD1-999early molecular responsebusiness

description

A reduction in BCR-ABL1/ABL1IS transcript levels to &lt

yearjournalcountryeditionlanguage
2019-05-06
10.3390/ijms20092226http://hdl.handle.net/20.500.11769/364601